References
- Knight JA, Skol AD, Shinde A, et al Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009;113:5575–5582.
- Zhong Y, Chen B, Feng J, et al The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes of acute myeloid leukemia. Leuk Lymphoma 2010;51:1115–1120.
- Damm F, Heuser M, Morgan M, et al Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2010;28:578–585.
- Moon JH, Sohn SK, Lee MH, et al BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leuk Res 2010;34:166–172.
- Kuptsova N, Kopecky KJ, Godwin J, et al Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 2007;109:3936–3944.
- Kimchi-Sarfaty C, Oh JM, Kim IW, et al A ‘silent’ polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525–528.
- Faa V, Coiana A, Incani F, Costantino L, Cao A, Rosatelli MC. A synonymous mutation in the CFTR gene causes an aberrant splicing in an Italian patient affected by a mild form of cystic fibrosis. J Mol Diagn 2010 Feb 26. [Epub ahead of print].
- Thi Tran HT, Takeshima Y, Surono A, Yagi M, Wada H, Matsuo M. A G-to-A transition at the fifth position of intron-32 of the dystrophin gene inactivates a splice-donor site both in vivo and in vitro. Mol Genet Metab 2005;85:213–219.
- Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 2005;15:693–704.
- Fong PC, Boss DS, Yap TA, et al Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123–134.
- Baxter EJ, Scott LM, Campbell PJ, et al Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
- Hitoshi Y, Lin N, Payan DG, Markovtsov V. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol 2010;91:189–200.